Semaphorin 3A (SEMA3A), protocadherin 9 (PCdh9), and S100 calcium binding protein A3 (S100A3) as potential biomarkers of carcinogenesis and chemoresistance of different neoplasms, including ovarian cancer — review of literature by Izycka, Natalia et al.
223
RE VIE W PAPER /  G y n E co lo G y
Ginekologia Polska
2019, vol. 90, no. 4, 223–227





Division of Gynecologic Oncology, Poznan University of Medical Sciences, 33 Polna St, 60–535 Poznan, Poland
e-mail: natka36@wp.pl
Semaphorin 3A (SEMA3A), protocadherin 9 (PCDH9), 
and S100 calcium binding protein A3 (S100A3) 
as potential biomarkers of carcinogenesis and 
chemoresistance of different neoplasms, including 
ovarian cancer — review of literature
Natalia Izycka1, Karolina Sterzynska2, Radoslaw Januchowski2, Ewa Nowak-Markwitz1
1Division of Gynecologic Oncology, Poznan University of Medical Sciences, Poznan, Poland 
2Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland
ABSTRACT
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. Its high mortality rate results from lack of 
adequate and sensitive methods allowing for the detection of the early stages of the disease, as well as low efficiency of 
the treatment, caused by the cytotoxic drug resistance of cancer cells. Unfortunately, tumours are able to develop new 
pathways and protective mechanisms that allow them to survive toxic conditions of chemotherapy. Therefore, intensive 
search for new genes and proteins involved in resistance to cytotoxic drugs is still needed, especially from a clinical point 
of view. The article presents an overview of the available literature on the role of semaphorin 3A (SEMA3A), protocadherin 
9 (PCDH9), and S100 calcium binding protein A3 (S100A3) in carcinogenesis and chemoresistance of various tumors 
including ovarian cancer. As it turns out, the role of described genes/proteins is not limited only to their native biological 
activity but they function also as an oncogenic or suppressor factors in the tumor development. Moreover, they can also 
play an important role in development of drug resistance, as it was shown in ovarian cancer cell lines.
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INTRODUCTION
Despite its relatively low incidence, ovarian cancer (OC) is 
the fifth leading cause of cancer-related deaths in women [1]. 
Most patients are diagnosed at late stages of the disease 
with overall survival rate of 30%. At the time of diagnosis, 
ovarian cancer is usually sensitive to most cytotoxix drugs, 
whereas during therapy, the cancer cells may develop drug 
resistance, which may cause ineffectiveness of further treatment 
lines, and hence is considered as one of the main reasons of such 
poor clinical outcomes of OC treatment. A standard first-line 
strategy for ovarian cancer is aggressive surgery accompanied 
by first- line chemotherapy with platinum and taxane 
agents. The most common cytotoxic drugs used in the second-
line treatment of OC are doxorubicin and topotecan. However, 
despite all of the recent research on surgical techniques and 
chemotherapy, the improvement in the outcomes of the disease 
is not satisfactory and approximately 80% of the patients will 
present with recurrence within 12 to 18 months after initial 
diagnosis and eventually succumb to OC [2].
The choice of cytotoxic drugs for treatment of 
OC relapse depends on patient’s reaction to first-line 
therapeutics. Traditionally, OC is divided in terms of response 
to initial platinum-based treatment into platinum-sensitive, 
platinum-refractory and platinum-resistant. Patients that are 
platinum sensitive respond well to the first-line therapy, with 
platinum-free interval (PFI) of minimum 6 months. Platinum- 
refractory patients develop progression during the 
treatment with the use of platinum compounds. In platinum 
resistant cases, the initial response to treatment is good, 
but eventually the relapse within 6 months since the end 
224
Ginekologia Polska 2019, vol. 90, no. 4
www. journals.viamedica.pl/ginekologia_polska
of the treatment is observed [3]. In cases of platinum- 
resistant recurrence, second line treatment options consist 
of liposomal doxorubicin, topotecan, gemcitabine, or oral 
etoposide [4]. Unfortunately, the effectiveness of second-
line chemotherapy is usually low, at around 15 to 35% [5]
Despite all of described treatment options, the prognosis 
of advanced or recurrent disease remains poor. Late diagnosis 
at late clinical stage, tumoral heterogeneity and inherent or ac-
quired during treatment drug resistance of cancer cells are con-
sidered to be the main reasons of the poor clinical outcomes. 
There is a number of known and well described cellular 
mechanisms of drug resistance. The most important one is 
the active removal of the drug outside the cell involving 
the transporters of the ABC family [6]. Other mechanisms 
responsible for cytotoxic-drug resistance are: breaking the 
apoptotic signaling pathways, inactivating the drugs by 
binding to metallothionein or glutathione or using the de-
toxification enzymes, increase in the activity of pro-survival 
and anti-apoptotic pathways, reconstruction of damaged 
DNA, and forming mutations in the genes encoding pro-
teins that bind cytotoxic drugs [7]. Unfortunately, tumors 
are able to develop a range of different mechanisms that 
lead to gain of resistance to the abovementioned agents, 
both on the cellular and tissue levels. Currently, there are no 
specific markers allowing for prediction or detection of ovar-
ian cancer drug resistance. Therefore, intensive search for 
new genes and proteins involved in resistance to cytotoxic 
drugs is still needed, especially from a clinical point of view.
Although many drug resistance models have been 
described so far, cancer cells are still able to develop new 
pathways and protective mechanisms that allow them to 
survive toxic conditions. This indicates that drug resistance 
is a complex phenomenon with a variety of new and still 
undiscovered genes and processes to be involved in. 
Microarray- based studies of chemoresistance in OC proved 
this hypothesis and revealed a wide range of genes that 
were shown to be under- or overexpressed in drug resistant 
cancer cell lines. The results of the analyses indicate that new 
genes, previously unrelated and non-associated not only with 
drug-resistance but even with cancer development, may be 
involved in chemoresistance [8–10]. Semaphorin 3A (SEMA3A), 
protocadherin 9 (PCDH9), and S100 calcium binding protein 
A3 (S100A3) were discovered among the genes that exhibited 
changed expression and have not been previously associated 
with the development of drug resistance. The expression of all 
of these genes was shown to be altered in microarray- based 
studies conducted on ovarian cancer cell lines resistant to 
most commonly used cytotoxic drugs [11–13].
SEMAPHORIN 3A (SEMA3A)
SEMA3A belongs to a large family of membrane- bound 
and secreted proteins-semaphorins, which were initially 
known to play an important role in axonal guidance [14]. 
They can be classified into 8 classes (SEMA 1–7 and viral 
semaphorins). Class 3 semaphorins is the only type secreted 
in vertebrates, and consists of seven proteins (SEMA3A–G), 
which are secreted by several types of cells including neurons, 
epithelial cells, endocrine cells or cardiac muscle cells. They 
are expressed in the nucleus and cytoplasm of normal 
ovarian epithelium [15] and play a role in organogenesis 
and angiogenesis. Lately however, their wide expression and 
potential role in the tumor growth has been investigated. 
Recent studies had shown that SEMA3A, besides its 
anti- angiogenic role, might also serve as either tumor- 
inhibitory or tumor-promoting factor, depending on the 
microenvironment. Its antitumoral effect might be achieved 
by inhibiting cell migration and proliferation, reducing 
the adhesion or migration of tumor cells and promoting 
apoptosis [16]. SEMA3A being a candidate gene of tumor 
suppression was shown to be downregulated in several types 
of cancer, for example oral cancer, gastric cancer, breast cancer, 
prostate cancer as well as glioblastoma and OC. Moreover, the 
expression of SEMA3A protein usually significantly correlated 
with clinicopathological features of these neoplasms, such as: 
stage and grade of the disease, depth of invasion, presence 
of metastases and the survival [15, 17–22]. 
In gastric carcinoma, the underexpression of SEMA3A 
correlated with poor differentiation, depth of invasion, 
presence of metastases and vascular invasion as well as the 
advanced TNM stage. It also seemed to be an independent 
prognostic factor of poor survival. Furthermore, in in vitro 
studies on gastric cancer the overexpression of SEMA3A 
was shown to inhibit cell proliferation and migration [18]. In 
prostate cancer, positive expression of SEMA3A in tumor cells 
was associated with predictors of good prognosis such as lower 
pathological stage and lower preoperative PSA level [20]. On 
the other hand, decreased expression of SEMA3A in prostatic 
cancer cells was also found to be a predictor of resistance 
to hormonal treatment [23]. In OC, the underexpression 
of SEMA3A significantly correlated with FIGO stage, grade 
and presence of metastatic disease. However, no correlation 
between SEMA3A expression and histological type or size of 
the tumor was found in ovarian carcinoma [15].
On the contrary, in some neoplasms, like lung cancer, 
SEMA3 family was found to promote carcinogenesis. 
SEMA3A was investigated as a potential therapeutic target 
in eradication of lung cancer stem cells as the knockdown 
of SEMA3A expression resulted in total suppression of 
tumorigenicity of lung cancer [24]. 
In conclusion, SEMA3A expression seems to be an in-
dependent prognostic factor of overall survival of various 
types of neoplasms. It was proved that for gastric and OC the 
overall survival of the underexpressed SEMA3A group of 
patients was significantly shorter comparing to the group with 
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positive SEMA3A expression. It may suggest that SEMA3A 
may be an inhibitor of tumors of epithelial origin [15, 17, 18, 
21, 22, 24–26]. It is of general knowledge that metastatic and 
poorly differentiated tumor cells are usually more resistant to 
cytotoxic drugs. It would be of great interest to specify the role 
of SEMA3A in development of drug resistance, especially from 
clinical point of view. Some preliminary studies with the use of 
microarray based gene expression have already demonstrated 
that SEMA3A was one of the underexpresed genes in drug 
resistant ovarian cancer cell lines [11]. In paclitaxel resistant 
ovarian cancer cell lines, very high downregulation of the 
SEMA3A transcript level was observed [12].
As described before, there is an increasing evidence 
of the role of SEMA3A in carcinogenesis. However, little 
is known about its potential role in development of drug 
resistance. Since it is a serious tumor suppressor candidate, 
not only in OC but also in other tumors, it seems to be of 
great importance to examine its role in drug resistance 
development. 
PROTOCADHERIN 9 (PCDH9)
Another gene with noticeably altered expression revealed 
in microarray studies of drug resistant ovarian cancer cell lines, 
was PCDH9. PCDH9 (protocadherin 9) belongs to cadherin 
superfamily and is a calcium-dependent cell-cell adhesion 
molecule. It is expressed predominantly in the nervous 
system, however it was also observed in healthy tissues of the 
human body. Protocadherins have also been shown to play 
an important role in tumorigenesis, cell migration, survival and 
growth of different cancer tissues. Recently, various PCDHs 
including PCDH9 (and PCDH8, PCDH10, PCDH17, PCDH20) 
have been reported as candidate tumor suppressor genes 
in variety of cancers (e.g. prostate, gastric, hepatocellular 
cancer) [27–29]. The expression of PCDH9 in cancerous 
tissues of prostatic, gastric, hepatocellular cancers as well 
as non-nodal mantle cell lymphoma (MCL) and glioma was 
substantially lower in comparison to tissues of healthy organs 
[27–30]. Moreover, the expression of PCDH9 significantly 
inversely correlated with histological grade of those, and 
the findings on the protein and RNA levels are consistent. 
This might suggest that down-regulation of PCDH9 may be 
a factor in the carcinogenesis of these neoplasms, however 
the association between PCDH9 and the pathogenesis of 
these and other cancers remains elusive. What is more, 
significantly lower expression of PCDH9 was observed 
more frequently in high grade and worse histological type of 
tumors and was also associated with worse mean survival rate 
of glioma, gastric and prostatic cancer patients [27, 28, 30]. In 
prostatic cancer, significant downregulation of PCDH9 was 
shown during progression to the advanced or metastatic 
stage. Furthermore, lower PCDH9 expression correlated with 
shorter time to biochemical relapse and higher levels of PSA 
and the recurrence itself, as well as worse histological type 
and decreased overall survival [27]. Chen et al. observed 
that PCDH9 expression has been markedly reduced or 
completely lost in lymph node and hepatic metastases of 
gastric cancer. In this case, it also inversely correlated with 
tumor size, clinical stage and differentiation of the disease, 
and finally, patient survival. Interestingly, forced expression 
of PCDH9 gene in gastric cancer cell lines inhibited cancer 
cell growth and migration. The results of statistical analysis 
correlating PCDH9 expression with clinico-pathological data 
revealed that it might be considered as an independent 
prognostic factor for gastric cancer [28].
Another type of tumor where the relation of PCDH9 with 
the process of carcinogenesis was described is hepatocellular 
carcinoma. Zhu and colleagues had shown that PCDH9 plays 
a critical role in establishment of metastases by inhibiting 
the epithelial-mesenchymal transition of hepatocellular 
carcinoma cells, suggesting that it might serve as a key 
regulator of detachment and spreading cancer cells. They 
also proved that downregulation of PCDH9 expression 
correlated with increased malignant invasion and metastasis 
formation [29].
As outlined above, it is known that the expression of 
PCHD9 is downregulated in many tumor types and the loss of 
its expression may be related to more invasive phenotype [11]. 
However, the role of this phenomenon in the field of 
multidrug resistance development is scarce and insufficient. 
All of abovementioned research results strongly imply 
a tumor suppressor role of PCDH9 in the development and 
progression of human cancers like glioma, prostatic and 
gastric cancer, together with hepatocellular carcinoma. Thus, 
loss of its expression might be related to a more invasive 
and hence more resistant phenotype. Januchowski and 
colleagues, in their microarray- based studies had examined 
the PCDH9 gene expression in ovarian cancer cell lines 
resistant to cytotoxic drugs used in standard treatment of 
OC: paclitaxel, topotecan, doxorubicin and cisplatin [12, 13]. 
The studies revealed the statistically significant decrease in 
PCDH9 transcript levels in paclitaxel-resistant cell lines [12]. 
These results can serve as the starting point for more 
advanced research on the role of PCDH9 in the development 
of chemotherapy resistance. 
All of the results clearly indicate that PCDH9 might play 
a crucial role in carcinogenesis and forming of metastases 
followed by its potential role in chemoresistance development 
and suggest that the re-expression of PCDH9 might serve as 
a potential therapeutic strategy for cancer treatment. 
S100 CALCIUM BINDING PROTEIN A3 
(S100A3)
In humans, the S100 genes are known to encode 25 pro-
teins of calcium-binding protein family.  The S100 proteins 
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are located in cytoplasm and/or nucleus of different cells 
and they are involved in a large number of important cellular 
processes including cell cycle regulation, cell proliferation, 
differentiation, apoptosis, calcium homeostasis, inflamma-
tion, energy metabolism and migration/invasion [31]. Latest 
studies revealed that the S100 proteins also play crucial role 
in tumorigenesis. More importantly, they are involved in 
regulation of epithelial-mesenchymal transition and tumor 
microenvironment reorganization and hence they promote 
cancer progression and metastasis. The role of these proteins 
in tumorigenesis is mostly cell type specific and may include 
oncogenic or tumor-suppresive functions, depending on the 
type of cell and tumor. Their functional characteristics differ, 
depending on their extracellular environment. Many studies 
had shown higher expression of S100 protein in different 
types of cancers like gastric, hepatocellular or colorectal 
cancer and the overexpression of these proteins usually 
shows great clinical implications for the diagnosis, staging 
and prognosis of these tumors.
Within the wide range of S100 proteins the matricellular 
S100A3 is described lately as directly involved in 
tumorigenesis. The protein is expressed in various tissues 
and cell types and was found in different cell structures 
like cell membrane or the cytoplasm. It is encoded by the 
S100A3 gene and contains two EF-hand calcium binding 
motifs in humans. The results of some studies indicate that 
dysregulation of S100A3 expression and function contributes 
to pathological conditions such as cancer progression or/and 
metastases. The oncogenic role of S100A3 is still under 
investigation, however it has been shown that the inhibition 
of S100A3 expression in prostate cancer cell lines reduced 
cell viability and invasiveness. A positive correlation between 
S100A3 expression and tumor type and grade in neoplasms 
like astrocytoma, prostate and gastric cancer was found [31]. 
In gastric cancer, S100A3 upregulation correlates positively 
with the TNM stage and tumor differentiation, where higher 
levels of the protein were noticed for stages III and IV of the 
disease and in poorly differentiated tumors. Similarly, in 
colorectal cancer tissues, a notable increase in expression 
of this protein was detected, with the highest expression 
levels in the tumor cells and tumor interstitial regions and 
the significant reduction was observed after the cytotoxic 
treatment [32]. The S100A3 gene activation was also proven 
to be involved in tumorigenesis and tumor aggresiveness 
of hepatocellular carcinoma and prostate cancer [33, 34]. 
In the prostate cancer the positive correlation of 
S100A3 expression with tumor size was found. Moreover, 
silencing of the S100A3 gene led to marked reduction of 
tumor growth and final tumor size and mass [34]. Also, studies 
conducted on ovarian cancer cells revealed that elevated levels 
of S100A3 expression was found, especially in cells resistant 
to cisplatin, topotecan and paclitaxel [11, 12]. This shows 
that S100A3 inhibition may effectively induce tumor growth 
suppression and remain a promising option for molecular-
targeted anti-cancer therapies [34] and might also serve 
as a potential target for OC drug resistance reduction. [11].
SUMMARY
The article presents a overview of the available literature 
on the role of semaphorin 3A (SEMA3A), protocadherin 
9 (PCDH9), and S 100 calcium binding protein A3 (S100A3) 
in carcinogenesis and chemoresistance of various 
tumors. Until now, there is only few studies investigating 
the role of presented genes and proteins in OC and only 
one of them was performed on the human neoplastic 
lesions. Other studies were usually conducted with the use 
of ovarian cancer cell lines. Spreading the investigation to 
the human cancerous tissues and then analyzing the results 
and comparing with the clinical data would offer significant 
information about the actual role of the these genes and 
proteins in OC tumor growth, development of metastases 
and drug resistance. In addition, the proteins could become 
potential biomarkers of tumorigenesis and response to 
standard cytotoxic drugs and thus become an integral part 
of tailored treatment of OC. This could serve as an important 
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